RxDoctor Payments Data

Camil Kreit, MD

Family Medicine · Cleveland, TXNPI 1558423780

Payments from drug & device makers

$211,413in general payments, 2019–2025

Across 1,092 payments — averaging $193.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$195K
  • GSK$2K
  • AbbVie$2K
  • Bayer$998
  • Dexcom, Inc.$906
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$702
  • plus $11K from 54 others

What the payments were for

  • Food & beverage$18,86998%
  • Education$4002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca111$194,805
GSK83$1,542
AbbVie(2 entities)104$1,539
Bayer46$998
Dexcom, Inc.95$906
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC52$702
Novo Nordisk40$687
Paratek Pharmaceuticals, Inc.52$639
Mannkind Corporation29$580
Merck33$538
Lilly USA, LLC33$536
Harmony Biosciences LLC22$521
Amgen(2 entities)26$515
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)25$505
Sanofi-aventis U.S. LLC29$441
Sunovion Pharmaceuticals Inc.27$357
Amarin Pharma, Inc.19$345
Gilead10$306
Pfizer32$303
Otsuka America Pharmaceutical, Inc.13$281
Jazz Pharmaceuticals Inc.7$277
Eisai Inc.16$250
Astellas Pharma US Inc5$248
Indivior Inc.11$215
Inspire Medical Systems, Inc.6$206
Braeburn Inc.12$206
Idorsia Pharmaceuticals US Inc14$201
Axsome Therapeutics, Inc.9$189
Philips North America LLC5$186
Novartis8$163
Nestle Healthcare Nutrition Inc.8$140
Corcept Therapeutics5$114
Valeritas, Inc.4$105
Exact Sciences5$101
IBSA Pharma Inc.6$83
Globus Medical2$81
Impel Pharmaceuticals Inc.4$79
Scilex Pharmaceuticals Inc.5$79
Regeneron Healthcare Solutions, Inc.5$77
Insulet Corporation4$68
Johnson & Johnson(2 entities)4$66
Phathom Pharmaceuticals, Inc.4$62
Boehringer Ingelheim4$61
Lundbeck LLC3$61
Abbott3$55
Biohaven Pharmaceuticals, Inc.3$52
Melinta Therapeutics, LLC2$52
Aimmune Therapeutics, Inc.3$50
Medtronic3$50
Viatris Specialty LLC2$48
Biohaven Pharmaceutical Holding Company Ltd.2$47
Orexo US, Inc.3$47
Sumitomo Pharma America, Inc.2$44
Xeris Pharmaceuticals, Inc.2$44
Teva Pharmaceuticals USA, Inc.2$43
Nabriva Therapeutics, PLC2$43
Arbor Pharmaceuticals, Inc.3$41
Antares Pharma, Inc.2$39
ZOLL Respicardia, Inc.1$31
UCB, Inc.1$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$211,413 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$135,387
Medicare patients
146
Services billed
1,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Potassium273$1,047,222
MethitestMethyltestosterone42$255,286
OzempicSemaglutide225$246,783
MounjaroTirzepatide182$222,947
Glycopyrrolate66$218,002
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate89$195,184
Chlorzoxazone141$159,293
Trelegy ElliptaFluticasone/Umeclidin/Vilanter212$147,307
RybelsusSemaglutide103$140,587
Enbrel SureclickEtanercept15$125,014
KerendiaFinerenone81$106,660
Breztri AerosphereBudesonide/Glycopyr/Formoterol134$88,845
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl312$80,611
Soliqua 100-33Insulin Glargine/Lixisenatide100$80,362
NuzyraOmadacycline Tosylate14$76,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$687$387,370328 claims
Lilly USA, LLCMounjaro$536$222,947182 claims
AstraZenecaBreztri Aerosphere, Farxiga, Airsupra$194,805$219,809319 claims
AbbVieVraylar, Qulipta, Linzess, Ubrelvy$1,539$217,224182 claims
GSKTrelegy Ellipta$1,542$147,307212 claims
BayerKerendia$998$106,66081 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$441$80,362100 claims
Paratek Pharmaceuticals, Inc.Nuzyra$639$76,66414 claims
Johnson & JohnsonXarelto$66$74,52886 claims
Axsome Therapeutics, Inc.Auvelity$189$63,11455 claims
Otsuka America Pharmaceutical, Inc.Rexulti$281$59,62539 claims
PfizerEliquis$303$58,83148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Cleveland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →